Virally Induced Cancers

  • Ravinder S. Gogia
  • Shawnbir Gogia
  • Sarah T. Arron


Immunosuppressed patients are at particular risk for skin cancers caused by, or associated with, viral infection. This chapter reviews three viral-associated skin cancers: human herpesvirus-8-associated Kaposi’s sarcoma, Merkel cell polyomavirus-associated Merkel cell carcinoma, and HPV-associated cutaneous squamous cell carcinoma.


Virus Cancer Squamous cell carcinoma Merkel cell carcinoma Kaposi’s sarcoma 



Acquired immunodeficiency syndrome


American Joint Committee on Cancer


Actinic keratosis


Basal cell carcinoma


Cytokeratin 20


Chronic lymphocytic leukemia


Cutaneous squamous cell carcinoma


Epidermal growth factor receptor


Epidermodysplasia verruciformis


Highly active antiretroviral treatment


Human herpesvirus-8


Human immunodeficiency virus


Human papilloma virus


Immune reconstitution inflammatory syndrome


Keratinocyte carcinoma


Kaposi’s sarcoma


Kaposi’s sarcoma-associated herpesvirus


Latency-associated nuclear antigen


Large T antigen


Merkel cell carcinoma


Multicentric Castleman’s Disease


Merkel cell polyomavirus


Neuron-specific enolase


Primary effusion lymphoma




Surveillance, epidemiology, and end results program


Sentinel lymph node biopsy


Solid organ transplant recipients


Thyroid transcription factor-1


Ultraviolet radiation


Vascular endothelial growth factor


Viral G protein-coupled receptor


Viral IL-6


  1. 1.
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44. Scholar
  2. 2.
    Arron ST, Jennings L, Nindl I, et al. Viral oncogenesis and its role in nonmelanoma skin cancer. Br J Dermatol. 2011;164:1201–13. Scholar
  3. 3.
    Arron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Investig Dermatol. 2011;131:1745–53. Scholar
  4. 4.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975–83. Scholar
  5. 5.
    Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80. Scholar
  6. 6.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–91. Scholar
  7. 7.
    Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445:21–34. Scholar
  8. 8.
    Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. Scholar
  9. 9.
    Kempf W, Mertz KD, Hofbauer GFL, Tinguely M. Skin cancer in organ transplant recipients. Pathobiology. 2013;80:302–9. Scholar
  10. 10.
    Connolly K, Manders P, Earls P, Epstein RJ. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Cancer Treat Rev. 2014;40:205–14. Scholar
  11. 11.
    Alter M, Satzger I, Mattern A, et al. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology (Basel). 2013;227:289–94. Scholar
  12. 12.
    Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Schwartz RA. Verrucous carcinoma of the skin and mucosa. J Am Dermatol. 1995;32:1–21; quiz 22–4.CrossRefGoogle Scholar
  14. 14.
    Vandeweyer E, Sales F, Deraemaecker R. Cutaneous verrucous carcinoma. Br J Plast Surg. 2001;54:168–70. Scholar
  15. 15.
    Sterling JC. Human papillomaviruses and skin cancer. J Clin Virol. 2005;32:67–71. Scholar
  16. 16.
    Bhat P, Mattarollo SR, Gosmann C, et al. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev. 2011;239:85–98. Scholar
  17. 17.
    Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329–39. Scholar
  18. 18.
    Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138:758–63.CrossRefPubMedGoogle Scholar
  19. 19.
    Crum-Cianflone N, Hullsiek KH, Satter E, et al. Cutaneous malignancies among HIV-infected persons. Arch Intern Med. 2009;169:1130–8. Scholar
  20. 20.
    Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50. Scholar
  21. 21.
    Arnold AW, Hofbauer GFL. Human papillomavirus and squamous cell cancer of the skin--epidermodysplasia verruciformis-associated human papillomavirus revisited. Curr Probl Dermatol. 2012;43:49–56. Scholar
  22. 22.
    Zampetti A, Giurdanella F, Manco S, et al. Acquired epidermodysplasia verruciformis: a comprehensive review and a proposal for treatment. Dermatol Surg. 2013;39:974–80. Scholar
  23. 23.
    Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24:S1–S10. Scholar
  24. 24.
    Jackson S, Harwood C, Thomas M. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 2000;14(23):3065–73. Scholar
  25. 25.
    Iftner T, Elbel M, Schopp B, et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J. 2002;21(17)):4741–8.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005;125:93–7. Scholar
  27. 27.
    Bavinck JNB, Plasmeijer EI, Feltkamp MCW. β-Papillomavirus infection and skin cancer. J Investig Dermatol. 2008;128:1355–8. Scholar
  28. 28.
    Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64:1051–9. Scholar
  29. 29.
    Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32:327–34. Scholar
  30. 30.
    Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149:402–10. Scholar
  31. 31.
    Miller SJ. Staging cutaneous squamous cell carcinoma. JAMA Dermatol. 2013;149:472–4. Scholar
  32. 32.
    Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American joint committee on cancer criteria and a proposed alternative system. JAMA Dermatol. 2013;150:19. Scholar
  33. 33.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78. Scholar
  34. 34.
    Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26:1340–4. Scholar
  35. 35.
    Hasan S. The role of postoperative radiation and chemoradiation in Merkel cell carcinoma: a systematic review of the literature. Front Oncol. 2013;3:276. Scholar
  36. 36.
    Eng TY, Boersma MG, Fuller CD, et al. A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol. 2007;30:624–36. Scholar
  37. 37.
    Kuwamoto S. Recent advances in the biology of Merkel cell carcinoma. Hum Pathol. 2011;42:1063–77. Scholar
  38. 38.
    Senchenkov A, Moran SL. Merkel cell carcinoma. Plast Reconstr Surg. 2013;131:771e–8e. Scholar
  39. 39.
    Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100. Scholar
  40. 40.
    Shuda M, Feng H, Kwun HJ, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci. 2008;105:16272–7. Scholar
  41. 41.
    Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37:20–7. Scholar
  42. 42.
    Zhan FQ, Packianathan VS, Zeitouni NC. Merkel cell carcinoma: a review of current advances. J Natl Compr Cancer Netw. 2009;7:333–9.CrossRefGoogle Scholar
  43. 43.
    Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58:375–81. Scholar
  44. 44.
    Pectasides D. Merkel cell cancer of the skin. Ann Oncol. 2006;17:1489–95. Scholar
  45. 45.
    Campillo R, Gil-Carcedo E, Alonso D, et al. Primary cutaneous neuroendocrine carcinoma, Merkel cell carcinoma. Case series 1991–2012. Acta Otorrinolaringol. 2013;64:396–402. Scholar
  46. 46.
    Buell JF, Trofe J, Hanaway MJ, et al. Immunosuppression and Merkel cell cancer. Transplant Proc. 2002;34:1780–1.CrossRefPubMedGoogle Scholar
  47. 47.
    Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: review. Adv Anat Pathol. 2009;16:135–44. Scholar
  48. 48.
    Schrama D, Ugurel S, Becker JC. Merkel cell carcinoma. Curr Opin Oncol. 2012;24:141–9. Scholar
  49. 49.
    Becker JC. Merkel cell carcinoma. Ann Oncol. 2010;21:vii81–5. Scholar
  50. 50.
    McCalmont TH. Connect the dots. J Cutan Pathol. 2013;40:921–3. Scholar
  51. 51.
    Lin Z, McDermott A, Shao L, et al. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett. 2014;344:272–81. Scholar
  52. 52.
    Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. Lancet. 2002;359:497–8. Scholar
  53. 53.
    Sihto H, Kukko H, Koljonen V, et al. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009;101:938–45. Scholar
  54. 54.
    Triozzi P, Fernandez A. The role of the immune response in Merkel cell carcinoma. Cancers. 2013;5:234–54. Scholar
  55. 55.
    Stetsenko GY, Malekirad J, Paulson KG, et al. p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. Am J Clin Pathol. 2013;140:838–44. Scholar
  56. 56.
    Bichakjian CK, Olencki T, Alam M, Andersen JS. Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Netw. 2014;12(3):410–24.CrossRefPubMedGoogle Scholar
  57. 57.
    Miller NJ, Bhatia S, Parvathaneni U, et al. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options in Oncol. 2013;14:249–63. Scholar
  58. 58.
    Ruocco E, Ruocco V, Tornesello ML, et al. Kaposi’s sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol. 2013;31:413–22. Scholar
  59. 59.
    Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008;59:179–206; quiz 207–8. Scholar
  60. 60.
    Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Buonaguro FM, Tornesello ML, Beth Giraldo E, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer. 1996;65:25–8.<25::AID-IJC5>3.0.CO;2-3.CrossRefPubMedGoogle Scholar
  62. 62.
    Moore PS, Chang Y. Kaposi’s sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am J Epidemiol. 1998;147:217–21.CrossRefPubMedGoogle Scholar
  63. 63.
    Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol. 2003;57:609–39. Scholar
  64. 64.
    Ma T, Jham BC, Hu J, et al. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci U S A. 2010;107:14363–8. Scholar
  65. 65.
    Sodhi A, Montaner S, Patel V, et al. The Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60(17):4873–80.PubMedGoogle Scholar
  66. 66.
    Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3(1):23–36.CrossRefPubMedGoogle Scholar
  67. 67.
    Moses AV, Jarvis MA, Raggo C, et al. Kaposi’s sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol. 2002;76(16):8383–99. Scholar
  68. 68.
    Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc. 2002;77:941–9. Scholar
  69. 69.
    Godden-Kent D, Talbot SJ, Boshoff C, et al. The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol. 1997;71:4193–8.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Friborg J, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889–94. Scholar
  71. 71.
    Eaton C, Dorer R, Aboulafia DM. Human Herpesvirus-8 infection associated with Kaposi sarcoma, multicentric Castleman’s disease, and plasmablastic microlymphoma in a man with AIDS: a case report with review of pathophysiologic processes. Pathol Res Int. 2011;2011:1–6. Scholar
  72. 72.
    Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839–42.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Grayson W, Pantanowitz L. Histological forms of cutaneous Kaposi sarcoma. Diagn Pathol. 2008;3:31. Scholar
  75. 75.
    Iscovich J, Boffetta P, Franceschi S, et al. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000;88:500–17.CrossRefPubMedGoogle Scholar
  76. 76.
    Schneider E, Whitmore S, Glynn KM, Dominguez K. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recomm Rep. 2008;57(RR-10):1–12.PubMedGoogle Scholar
  77. 77.
    Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204–10.CrossRefPubMedGoogle Scholar
  78. 78.
    Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28(4):453–65. Scholar
  79. 79.
    Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. Cancer. 2004;100:2644–54. Scholar
  80. 80.
    Sasco AJ, Jaquet A, Boidin E, et al. The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One. 2010;5:e8621. Scholar
  81. 81.
    Bower M. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23:5224–8. Scholar
  82. 82.
    Lesnoni La Parola I, Masini C, Nanni G, et al. Kaposi’s sarcoma in renal-transplant recipients: experience at the Catholic University in Rome, 1988-1996. Dermatology (Basel). 1997;194:229–33.CrossRefGoogle Scholar
  83. 83.
    Boshoff C, Weiss RA. Epidemiology and pathogenesis of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond Ser B Biol Sci. 2001;356:517–34. Scholar
  84. 84.
    Schwartz RA. Kaposi's sarcoma: An update. J Surg Oncol. 2004;87:146–51. Scholar
  85. 85.
    Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med. 2013;137:289–94. Scholar
  86. 86.
    Sullivan RJ, Pantanowitz L, Casper C, et al. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma–associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008;47:1209–15. Scholar
  87. 87.
    Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80.PubMedGoogle Scholar
  88. 88.
    Patel S, Xiao P. Primary effusion lymphoma. Arch Pathol Lab. 2013.
  89. 89.
    Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–38. Scholar
  90. 90.
    Ramdial PK, Chetty R, Singh B, et al. Lymphedematous HIV-associated Kaposi’s sarcoma. J Cutan Pathol. 2006;33:474–81. Scholar
  91. 91.
    Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol. 2013;68:313–31. Scholar
  92. 92.
    Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol. 2007;8:167–76. Scholar
  93. 93.
    Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–23. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ravinder S. Gogia
    • 1
  • Shawnbir Gogia
    • 2
  • Sarah T. Arron
    • 1
  1. 1.Department of DermatologyUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.School of Medicine, University of California, San FranciscoSan FranciscoUSA

Personalised recommendations